Barclays analyst Gena Wang raised the firm’s price target on Beam Therapeutics to $42 from $26 and keeps an Equal Weight rating on the shares. The company’s Q4 was largely in line and it reiterated a cash position of $1.2B with a runway into 2027 and on-track development of clinical pipelines, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BEAM:
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics, Inc. (BEAM) Q4 Earnings Cheat Sheet
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Beam Therapeutics upgraded to Overweight from Neutral at JPMorgan